AP
ITCI

AHL Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

AHL Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-38,563
Closed -$587K – 1206
2016
Q3 		$587K Buy
+38,563
New +$1.56M 0.02% 780

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AHL Partners's ITCI Position: Q4 2016 in Review

AHL Partners sold out of Intra-Cellular Therapies Inc. (ITCI) in Q4 2016, closing a stake of 38,563 shares — an estimated $587K sold.

AHL Partners first reported a position in ITCI in Q3 2016 and held it in 1 quarter. The position peaked at $587K in Q3 2016. 129 funds tracked by Wall St. Rank hold ITCI as of Q4 2016.

  • AHL Partners reported no remaining Intra-Cellular Therapies Inc. position as of Q4 2016 after selling out during the quarter.
  • AHL Partners sold 38,563 Intra-Cellular Therapies Inc. shares in Q4 2016, an estimated $587K.
  • AHL Partners first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 1 quarter.
  • AHL Partners's Intra-Cellular Therapies Inc. position peaked at $587K in Q3 2016.
  • 129 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2016.

Based on AHL Partners's 13F filing for Q4 2016, filed 14 Feb 2017.